Articles On Pharmaust (ASX:PAA)

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week It has been...

After securing ethics approval, PharmAust (ASX: PAA) is gearing up to begin a phase I clinical trial in the December quarter, which will assess its monepantel drug in patients with motor neurone disease. Ethics approval from Monash Health g...

The Phase I clinical trial of lead drug Monenpantel in humans is an exciting development after earlier announced encouraging pre-clinical studies. Clinical stage oncology company, PharmAust Limited (ASX:PAA), is set to commence the Phase I...

PharmAust (ASX:PAA) has announced it will proceed with a new phase one clinical trial to assess monepantel in patients with amyotrophic lateral sclerosis/motor neurone disease.

Wall Street mixed, as iron ore and oil gain The US stock market finished mixed, with energy being the main winner as oil prices rose. The global oil-price benchmark hit a two-year high at US$70, after OPEC said it sees more oil demand this...

The appointment of Dr Kim Agnew will support PharmaAust’s effort in its effort to progress to Phase III trials of its lead Monepantel drug. Clinical stage oncology company, PharmAust (ASX:PAA), has appointed a highly experienced executive t...

Clinical stage oncology company PharmAust (ASX: PAA) has appointed Dr Kim Agnew as the new principal investigator for its phase IIb veterinary clinical trial testing anti-cancer drug monepantel in pet dogs with treatment-naïve B-cell lymph...

The federal government’s “patent box” initiative caught the eye of Australia’s biotech sector in Tuesday night’s Budget. Speaking with Stockhead, a number of ASX biotechs were broadly positive about the announcement. However, some industry...

Summary Neuren Pharmaceuticals obtained a Canadian patent grant for trofinetide, with a patent term that extends to January 2032. Health technology company Medibio Limited has secured a pre-submission meeting with the FDA for a new 510...

PharmAust (ASX:PAA) has announced it will be conducting a half-dozen clinical trials through the second half of next year as it works to cure cancer in both dogs and humans as well as viral and neurological diseases. In a quarterly update,...

Six dogs have completed PharmAust’s (ASX: PAA) phase IIb trial evaluating its lead drug monepantel (MPL) in the most prevalent cancer in canines B-cell lymphoma. During the March quarter, PharmAust revealed six dogs with stage four to five...

Summary Oventus Medical witnessed growth in booked revenue and acceleration in telehealth bookings in Q3 FY21. ECS Botanics Holdings’ March 2021 quarter was action-packed with a major acquisition and multiple supply agreements. Despit...

Summary Regenerative medicine player Orthocell has announced positive results from the US 510(k) animal pilot study of CelGro®. AnteoTech has obtained firm commitments to raise AU$12M to accelerate its test product pipeline. Althou...

PharmAust (ASX:PAA), a clinical-stage oncology company, has updated on an interim analysis of its phase 2b trial on the monepantel blood plasma levels required to suppress B cell lymphoma growth in pet dogs.

Today’s crucial milestone takes the company a step further towards commercialisation of its Monepantel drug for canines with B-cell lymphoma. Clinical stage oncology company, PharmAust (ASX:PAA), has just announced that the Phase IIb trial...

An interim analysis of a phase IIb trial conducted by clinical-stage oncology company PharmAust (ASX: PAA) has provided supportive evidence of a therapeutic window for lead drug candidate monepantel to be used in the treatment of B-cell lym...

Clinical-stage oncology company PharmAust (ASX:PAA) has announced the receipt of over $750,000 from the Australian government under the R&D Tax Incentive program.

Clinical-stage oncology company PharmAust (ASX: PAA) has received a hefty rebate from the Australian Tax Office under the national research and development tax incentive scheme for the work of its wholly-owned subsidiaries Epichem Pty Ltd a...

The ASX closed upwards again and all sectors were in the green. The ASX 200 rose 0.61 per cent to 6,928 points and the ASX Emerging Companies Index rose 0.52 per cent to 2,046 points. Topping the list of best performing sectors were energy...

Further pre-clinical testing of PharmAust’s (ASX: PAA) monepantel (MPL) and monepantel sulphone (MPLS) drugs continues to demonstrate antiviral activity in cultured cell infection models of SARS-CoV2 – the virus causing the global COVID-19...

The ASX picked up where it left off before the Easter break with another day of gains. The ASX 200 rose 0.84 per cent to 6,886 points and the ASX Emerging Companies Index rose 1.17 per cent, closing at 2,036 points. Utilities and energy wer...

PharmAust (ASX: PAA) has completed assessment of the first five dogs in a phase IIb trial of its anti-cancer drug monepantel on treatment-naïve B cell lymphoma in canines, revealing only minimal side effects. The biotech company started the...

Source: janews, Shutterstock Summary ASX-listed cannabis player Botanix Pharmaceuticals has obtained ethics approval for BTX 1702 Phase 1b trial. Oncology player PharmAust PharmAust provided an update on its Phase IIb trial evaluating...

Epichem, the subsidiary of ASX-listed PharmAust (ASX:PAA), has signed a licensing agreement with Illinois-based Thermaquatica, to develop and promote a disruptive waste-to-fuels technology. The technology, Oxidative Hydrothermal Dissolution...

Source: S_L, Shutterstock Summary Epichem has signed a license deal with Thermaquatica for the research and development of an innovative waste to fuel conversion technology. Epichem will be looking for the government’s help and projec...

PharmAust’s (ASX: PAA) subsidiary Epichem has inked a licencing deal that will see it research, develop and promote a disruptive flow reactor technology that converts waste to fuel. Thermaquatica founder and chief technology officer Ken And...

Wall Street rallies led by tech Dow Jones and S&P 500 trimmed losses from the last few days, rising by 0.32% and 0.70% respectively overnight. Tech heavy NASDAQ rose by 1.23%, led by Tesla which was higher by 2.31%. The rally was mainly...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

COVID-19 vaccines have reached Australia but ASX stocks that were making anti-COVID 19 drugs or tests are pushing on. The outbreak of the pandemic caused a number of ASX companies (big and small) to pivot to fighting COVID-19. In the last f...

Biotech company PharmAust (ASX: PAA) has officially begun recruitment for the phase IIb trial of its lead anti-cancer drug monepantel (MPL) on canine lymphoma and has put a call out for more dogs to participate. The trial will test the effe...

Biotechnology firm PharmAust (ASX: PAA) is looking to recruit more canines with B-cell lymphoma to a new Phase IIb trial evaluating a re-formulation of its lead anti-cancer drug monepantel, which has been shown to be effective in dogs that...

Following a successful phase IIa trial using monepantel (MPL) to treat canine lymphoma, PharmAust’s (ASX: PAA) phase IIb study has begun. The recent phase IIa trial using monepantel to treat B-cell lymphoma in canines resulted in tumour reg...

Summary Epichem, PharmAust’s wholly-owned subsidiary, has obtained WasteSorted e-Waste Grant worth A$200K from WA Government New Industries Fund. The grant will see Epichem use Oxidative Hydrothermal Dissolution technology for converti...

It’s been another positive day on the ASX in the wake of Democrats gaining control of the US Senate – but small caps have once again underperformed their larger peers. The Small Ordinaries index of 200 small-cap companies closed Friday up 1...

Summary PharmAust Ltd (ASX:PAA) announced that it is working closely with Leiden University Medical Centre (LIUMC) on detailed research around Monepantel (MPL) coronavirus testing.  The study with Dr Martjin van Hemert at LUMC is to co...

Summary PharmAust and the ONJCRI researchers to investigate cancer genomes in detail and match activity variations. The Company stated that these investigations are intended to determine the mechanism of action of MPL on cancer cells....

ASX large cap biotech Mesoblast (ASX:MSB) is not alone in fighting Acute Respiratory Distress Syndrome (ARDS). ARDS is a disease that hinders the lungs’ ability to operate and is a major culprit of COVID-19 deaths. Essentially it causes lun...

Oncology company PharmAust (ASX: PAA) has posted a strong quarter of business activity, led by a hefty grant last month for a Phase 1 clinical trial to investigate the effects of lead drug monepantel on humans with motor neurone disease. Th...

Clinical-stage oncology company PharmAust (ASX: PAA) has announced the Olivia Newton-John Cancer Research Institute (ONJCRI) is investigating the anti-cancer mechanism of its flagship drug candidate monepantel. ONJCRI’s work is being partly...

PharmAust (ASX: PAA) is set to test the ability of its monepantel and monepantel sulfone drugs on their ability to inhibit coronavirus SARS-CoV-2 infection, the virus behind the COVID-19 global pandemic. The company has executed a service a...

Motor neurone disease (MND) charity FightMND has awarded oncology company PharmAust (ASX: PAA) a grant for a Phase 1 trial to examine the effects of its flagship drug candidate monepantel on the disease. PharmAust will receive $881,085 for...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The health sector made a bit of progress over the last fortnight, with 64 small-cap life sciences gaining ground and just 52 losing it. Another 15 companies were flat....

Oncology company PharmAust (ASX: PAA) has provided a timely update to the market concerning developments of its lead drug candidate, monepantel (MPL). PharmAust is currently progressing the drug in a trifecta of pathways including treating...

Oncology company PharmAust (ASX:PAA) will continue with the development of its Monepantel cancer treatment, including a progression towards clinical trials to demonstrate the drug’s effectiveness against COVID-19. The announcement comes aft...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Determined to become one of the first companies to develop an active treatment for COVID-19, oncology company PharmAust (ASX: PAA) has reported it has successfully repeated a second round of in-vitro anti-viral confirmatory testing, demonst...

PharmAust (ASX: PAA) subsidiary Epichem has entered into a 50:50 joint venture agreement with Western Australia-based private company Obsidian Minerals to develop a novel and disruptive waste-to-fuels technology using an oxidative non-catal...

Oncology company PharmAust (ASX: PAA) has narrowed its losses for the full year as it celebrated many achievements in the overall development of its lead cancer drug, monepantel (MPL). MPL is a veterinary drug registered for use as a wormic...

Preliminary research findings on PharmAust’s (ASX: PAA) lead candidates monepantel and monepantel sulfone have demonstrated that application of the drugs on human respiratory cells can inhibit the progression of (severe acute respiratory sy...